Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults
Clinical Pharmacology & Therapeutics · 2026-04 · 119 (4) · 1095-1104
DOI: 10.1002/cpt.70219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 01.02.2026. Verfasst von Pablo Salcedo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U…. Hauptthemen laut MEDLINE: Citalopram, Morphine, Cannabidiol, Analgesics, Opioid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cannabidiol (CBD) is one of the most abundant bioactive cannabinoids. Research has demonstrated CBD’s ability to inhibit metabolic enzymes like cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT), potentially leading to drug interactions. However, clinical knowledge gaps remain, particularly with regard to drugs that are more commonly taken by consumers of unregulated CBD products. This study aimed to characterize the effects of daily CBD consumption, at doses typical of unregulated CBD products, on the pharmacokinetics of citalopram and morphine. These two commonly prescribed medications are metabolized by CYPs and UGTs, respectively. This open‐label, sequential study involved two cohorts of 20 healthy participants. Cohort one received a single dose of citalopram (20 mg) on days 1 and 13, with CBD (2.5 mg/kg twice daily) administered for 12 days. Cohort two received a single dose of morphine (15 mg) on days 1, 4, and 11, with CBD (2.5 mg/kg twice daily) given for 9 days. The geometric mean ratio (GMR, [90% confidence interval]) for citalopram with and without CBD for 12 days was 1.43 (1.34–1.52) for the area under the plasma concentration–time curve (AUC 0−inf ) and 1.12 (1.06–1.17) for the maximum observed plasma concentration ( C max ). The GMR for AUC 0−inf and C max for morphine coadministered with CBD compared to morphine alone was 1.06 (0.96–1.16) and 1.19 (1.05–1.35), respectively. For morphine with CBD for 9 days compared to morphine alone, the GMR for AUC 0−inf and C max was 1.12 (1.00–1.26) and 1.11 (0.94–1.30), respectively. While a significant pharmacokinetic interaction between CBD and citalopram was observed, interactions between CBD and morphine, as well as its metabolites, were limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Spaulding Clinical Research, West Bend, Wisconsin, USA.
ORCID-Profile: Pablo Salcedo, Donna A Volpe, Anik Chaturbedi, Aanchal Shah, Ashok Krishna, Paula L Hyland, Giri Vegesna, Cheng-Hui Hsiao, Ryan De Palma, Melanie Fein, Rodney Rouse, Jeffry Florian
Zitieren
APA
Salcedo, P., Volpe, D. A., Chaturbedi, A., Shah, A., Krishna, A., Hyland, P. L., Vegesna, G., Hsiao, C. H., De Palma, R., Fein, M., Rouse, R., & Florian, J. (2026). Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults. Clinical Pharmacology & Therapeutics, 119(4), 1095-1104. https://doi.org/10.1002/cpt.70219
Vancouver
Salcedo P, Volpe DA, Chaturbedi A, Shah A, Krishna A, Hyland PL, et al. Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults. Clinical Pharmacology & Therapeutics. 2026;119(4):1095-1104. doi:10.1002/cpt.70219
BibTeX
@article{Salcedo2026,
author = {Salcedo, Pablo and Volpe, Donna A and Chaturbedi, Anik and Shah, Aanchal and Krishna, Ashok and Hyland, Paula L and Vegesna, Giri and Hsiao, Cheng-Hui and De Palma, Ryan and Fein, Melanie and Rouse, Rodney and Florian, Jeffry},
title = {Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {4},
pages = {1095--1104},
doi = {10.1002/cpt.70219}
}
EUVIMED